HMRC EIS Approved investment

Please enter your details to request more information

PIONEERING THE NEXT GENERATION OF CANCER DIAGNOSTICS

  • Targeting 10.5x target returns*
  • Planned M&A exit Q4 2029

Led by industry-renowned biochemist Dr. Martin Burow (former Head of Asia Pacific at Thermo Fisher), we're not just developing new ways to detect cancer, we're changing the entire approach to how it's monitored, treated, and beaten.

The Opportunity:

  • Shares priced at £1.20. Post-money valuation: £18m
  • ISO 15189-accredited laboratory already operational
  • Company forecasting £61.75m revenue and £31.5m EBITDA by 2029
  • Distribution partnerships across Europe and Southeast Asia
  • Dual revenue model combining diagnostic testing with recurring hardware and consumables
  • Minimum investment £12,000
  • 30% Income Tax Relief on investments of up to £1 million per tax year (or up to £2 million where at least £1 million is invested into knowledge-intensive companies), subject to individual circumstances.
  • Capital Gains Tax Deferral, allowing capital gains from other assets to be deferred by reinvesting into qualifying EIS shares.
  • Capital Gains Tax-Free Growth, provided the shares are held for a minimum of three years and all EIS conditions continue to be met.
  • Loss Relief, which may reduce the effective downside risk if the investment does not perform as expected, subject to your personal tax position.
  • Inheritance Tax Relief, with qualifying investments generally becoming eligible for 100% Business Relief after two years, provided the relevant conditions are met.

EIS Tax Benefits

Investing through the Enterprise Investment Scheme (EIS) offers a range of government-backed tax incentives .

Why Frontier Diagnostics?

Frontier Diagnostics isn’t building laboratory technology in search of a market.


The market already exists.


Cancer affects millions of patients every year, while clinicians continue to seek faster, more personalised diagnostic tools that support better treatment decisions.


Frontier’s proprietary circulating tumour cell platform has been developed to address that need, providing clinically relevant information from a routine blood draw, without the need for invasive tissue biopsies.


As adoption of precision medicine continues to accelerate, management believes Frontier Diagnostics is well positioned to become part of the future standard of cancer care.

To be able to deal with your enquiry effectively we will need to contact you via telephone and/or email. By enquiring you consent to being contacted and you consent to your data being stored in accordance with European GDPR regulations. Privacy Policy


Disclaimer: Any person accessing the website and considering potential investment opportunities featured on the website should make their own commercial assessment and could benefit from the advice of an appropriately authorised or regulated financial advisor. This website should not be construed as advice or a personal recommendation to any prospective investor. Investments of this nature carry risks to your capital and can go up or down. Past performance is not indicative of future results.

*Based on company forecasts. See the investment memorandum for more details. Past performance is not always indicative of future performance.